Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted ...

Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, ...

For years, the search for a stem cell donor has felt like a quest for a rare key-one that fits a lock with eight intricate tumblers, each representing a genetic marker.

Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus ...

Both studies provide new insights into how ropeginterferon alfa-2b may help people living with these chronic blood cancers. Martin Steinhart, CEO of AOP Health, concludes: “AOP Health was founded to ...

BeOne Medicines Ltd. , a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology ...

Presentation included previously disclosed primary results from the pivotal ARES Phase 3 single-arm trial evaluating MaaT013 (Xervyteg) in treating refractory severe acute Graft-versus-Host Disease ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Black race, regardless of cytogenetics, was found to be associated with poorer survival in a 30-year retrospective analysis of clinical trials involving patients with acute myeloid leukemia (AML) ...

Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, today announced new data from the company-sponsored ASTX030-01 and ...

Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...